Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Large-scale comparative study of cancer trends in China and the USA

Cancer is currently the most common cause of death in most developed countries around the world. In the USA, comprehensive progress in cancer research, prevention, and care has resulted in reduced rates of cancer since the 1990s, indicating that these strategies could also benefit other countries, such as China, where the cancer burden is steadily increasing.

31 Mar 2022

Magneto-activated natural killer cells for treating solid tumors

Cancer immunotherapy-;a type of treatment that enlists our own immune cells to attack tumors-;has revolutionized the way that many types of cancer are treated. One type of immunotherapy under investigation uses natural killer cells, a type of immune cell that can seek and destroy harmful cells.

28 Mar 2022

Equine hepatitis viruses help gain new insights into the behavior of hepatitis C virus in humans

Research comparing viruses found in humans and horses provides insights that may aid vaccine development.

2 Mar 2022

New trial aims to test a non-invasive treatment for early-stage liver cancer

Researchers are set to trial a non-invasive treatment for inoperable early-stage liver cancer, thanks to an injection of over $2 million in federal government funding.

25 Feb 2022

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Novocure announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity.

25 Feb 2022

Discovery could lead to new treatment approach for people with alcohol-associated liver disease

Investigators at Cedars-Sinai have uncovered a new pathway that helps explain how consuming too much alcohol causes damage to the liver, specifically mitochondrial dysfunction in alcohol-associated liver disease.

22 Feb 2022

The logic that controls gene regulation in human cells discovered

A research group at the University of Helsinki has discovered the logic that controls gene regulation in human cells. In the future, this new knowledge can be applied to, for example, investigating cancers and other genetic diseases.

21 Feb 2022

Treatment with direct-acting antivirals reduces emergency visits, hospitalizations among hepatitis C patients

Researchers at Henry Ford Health System, as part of a national hepatitis C collaborative, report that patients with chronic hepatitis C who are treated with direct-acting antiviral medicines are less likely to be hospitalized or seek emergency care for liver and non-liver related health issues.

21 Feb 2022

Transformational $104 million gift will help VCU to expand treatment options for liver diseases

Virginia Commonwealth University will radically expand treatment options for liver and liver-related metabolic diseases thanks to a historic, transformational $104 million gift from Richard Todd Stravitz, M.D., and his family's Barbara Brunckhorst Foundation.

15 Feb 2022

Discovery may lead to new treatment approach for people with alcohol-associated liver disease

14 Feb 2022

Maternal metabolic syndrome can switch on imprinted gene associated with NAFLD in offspring

New research from North Carolina State University has found that an imprinted gene associated with development of non-alcoholic fatty liver disease (NAFLD) is switched on in mice who nurse from mothers with metabolic syndrome, even when those mice are not biologically related.

7 Feb 2022

Researchers find a way to interfere with the energy pathway that promotes liver cancer spread

The World Health Organization projects that starting in 2030, over a million people will die each year from liver cancer.

4 Feb 2022

Researchers develop new tool to determine patients' liver cancer risk after hepatitis C

Hepatitis C can now be effectively treated, thanks to modern drugs. However, despite having been cured, some patients can go on to develop liver cancer. Currently, biannual ultrasound screening is done to monitor for incipient cancer.

28 Jan 2022

Two-step strategy can help determine the risk of liver cancer after HCV cure

The results of the study, conducted from the Virgen del Rocío Hospital, reveal the importance of personalized medicine and evaluating each patient.

27 Jan 2022

Scientific review highlights the impact of coffee on digestive organs

A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.

19 Jan 2022

New pathways responsible for hepatocellular carcinoma identified

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is one of leading causes of cancer-related deaths globally, with more than 700,000 new cases and 600,000 estimated HCC deaths each year.

18 Jan 2022

ASTRO provides new guidance on the use of external beam radiation therapy for primary liver cancers

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary liver cancers using external beam radiation therapy (EBRT).

12 Jan 2022

Scientists describe dynamic genomic landscape of tumor heterogeneity in hepatocellular carcinoma

Clinician scientists and scientists from the National Cancer Centre Singapore and A*STAR's Genome Institute of Singapore, in collaboration with Singapore General Hospital, the National University Health System, Duke-NUS Medical School, Nanyang Technological University, and collaborators from China, Malaysia, Thailand and the Philippines, have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma (HCC).

13 Dec 2021

CRISPR/Cas9 gene editing enables sonodynamic therapy to effectively shrink tumors

Sonodynamic therapy uses ultrasound in combination with drugs to release harmful reactive oxygen species (ROS) at the site of a tumor.

8 Dec 2021

New approach to enhance the therapeutic efficacy of liver cancer immunotherapy

In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.

7 Dec 2021